Prometheus Biosciences (RXDX) reported promising results from two inflammatory disease studies on Wednesday, and RXDX stock catapulted by a triple-digit percentage.
The company studied its drug in patients with ulcerative colitis and Crohn's disease, two forms of irritable bowel disease. More than a quarter of ulcerative colitis patients and almost half of the Crohn's disease group entered remission 12 weeks after treatment.
Now, Prometheus is planning to run final-phase studies in 2023.
In premarket action on the stock market today, RXDX stock skyrocketed 176.2% near 99.60. That put shares on deck to open at a record high.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.